Vyluma
Manufacturing · New Jersey, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Building K Nj Center of Excellence 1019 ...Phone Number
(908) 367-7400Website
www.vyluma.comRevenue
$5.6 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
1
1
1
About Vyluma
Vyluma is a private biopharmaceutical company dedicated to developing innovative ophthalmic treatments, particularly topical eye drops, to address significant unmet needs in global eye health. The company focuses on conditions such as pediatric myopia, presbyopia, night vision disturbances, and acute ocular pain, aiming to improve patients' quality of life and preserve vision. Vyluma's leading candidate, NVK002, is poised to be the first pharmaceutical treatment to slow myopia progression in children, while NVK029 offers an alternative to traditional vision correction methods for presbyopia. Through partnerships with eye care clinicians, Vyluma is committed to transforming the standard of care with its promising pipeline of novel therapies.Explore more
Vyluma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Vyluma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Vyluma has new funding data
Earning: See what the market has to say on Vyluma recently announced quarterly report
Check if Vyluma has recently received funding, and reach out quickly before it becomes old news!
Click to see if Vyluma had a recent Job posting/layoffs
Check out if Vyluma is spiking on competitors!
Product Launch: Get notified when Vyluma launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Vyluma
Vyluma, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at Vyluma
Find 3 more new buyers
Compare Similar Companies to Vyluma
Compare insights from companies similar to Vyluma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Vyluma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Vyluma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Vyluma.
Vyluma Tech Stack
A closer look at the technologies used by Vyluma
Most Recent Scoops
Funding
Project
Spending/Investment, Funding
Executive Move
Executive Moves, Board of Directors
Executive Move
Executive Move
Vyluma News & Media
Vyluma Meets with FDA on Atropine Sulfate Ophthalmic Solution 0.01% Under Development to Treat Pediatric Myopia
Vyluma Discusses Response to FDA’s Questions and Clarifies Regulatory Pathway for its 505(b)(2) NDA, NVK002 to slow the progression of myopia in children.Vyluma Announces Marketing Authorization Application Validation for the European Union
Vyluma announces Marketing Authorisation Application (MAA) validation for the EU for NVK002 to slow the progression of pediatric myopia.Vyluma Announces FDA Acceptance of New Drug Application For NVK002, Its Novel Investigational Treatment For Pediatric Myopia
Bridgewater, NJ– June 6, 2023– Vyluma, Inc. (“Vyluma”), a biopharmaceutical company developing multiple assets for the treatment of refractive errors, announced today that the U.S. Food and Drug Administration (FDA) has... (Source: Drugs.com - New Drug Applications)Vyluma Announces FDA Acceptance of New Drug Application for NVK002, Its Novel Investigational Treatment for Pediatric Myopia
BRIDGEWATER, N.J., June 06, 2023 (GLOBE NEWSWIRE) -- June 6, 2023 – Vyluma, Inc. (“Vyluma”), a biopharmaceutical company developing multiple assets for the treatment of refractive errors, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for its lead compound, NVK002 (low dose atropine 0.01%) as a potential treatment for myopia in children. NVK002 is a proprietary, investigational, preservative-free eye drop administered night
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Vyluma
Sign Up For FreeTo access detailed company insights
Vyluma is a private biopharmaceutical company dedicated to developing innovative ophthalmic treatments, particularly topical eye drops, to address significant unmet needs in global eye health. The company focuses on conditions such as pediatric myopia, presbyopia, night vision disturbances, and acute ocular pain, aiming to improve patients' quality... Read More
